Back to News
Market Impact: 0.35
GSK: Why I'm Still Bullish After Strong Q3 Results
Source: seekingalpha.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
GSK reported third-quarter revenue growth of 5.7% and non-GAAP EPS growth of 8.2% quarter-on-quarter. Cabenuva sales reached $641 million, up 35.2% year over year.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
GSK0.70
More News
- UK Budget Tests Bond Markets as Fed, ECB and Oil Risks Loom
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong